Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 377	$ 500
Operating expenses:
Cost of revenue	3,614	585
Sales and marketing	19,318	8,895
General and administrative	41,041	25,420
Amortization of acquired intangible assets	1,784	146
Research and development	25,547	19,847
Total operating expenses	91,304	54,893
Net loss from operations	(90,927)	(54,393)
Other income (expense):
Interest expense	(1,272)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note	(1,273)	1,682
Loss on issue and offering costs - Senior Secured Convertible Note	(4,332)
Debt extinguishments loss - Senior Secured Convertible Notes	(5,434)	(3,715)
Debt forgiveness		300
Other income (expense), net	(12,311)	(1,733)
Loss before provision for income tax	(103,238)	(56,126)
Provision for income taxes
Net loss before noncontrolling interests	(103,238)	(56,126)
Net loss attributable to the noncontrolling interests	14,255	5,779
Net loss attributable to PAVmed Inc.	(88,983)	(50,347)
Less: Series B Convertible Preferred Stock dividends earned	(281)	(283)
Net loss attributable to PAVmed Inc. common stockholders	$ (89,264)	$ (50,630)
Per share information:
Net loss per share attributable to PAVmed Inc. - basic and diluted	$ (1.00)	$ (0.65)
Net loss per share attributable to PAVmed Inc. common stockholders – basic and diluted	$ (1.00)	$ (0.65)
Weighted average common shares outstanding, basic and diluted	89,076,078	77,515,767